ICOSLG (Inducible T Cell Costimulator Ligand)

Here, we have provided molecular characterization of biphasic FDCS. Prior such characterization seems to be unavailable in the literature.

Multivariate analysis identified CD83 IHC high expression as an independent predictor of non-SR cases. High CD83 expression is an independent prognostic factor in MTX-associated IDD-DLBCL, and combined evaluation may refine risk stratification and guide clinical decisions.

While the panel showed promising performance for distinguishing MRD-positive from MRD-negative samples, the limited MRD-positive cohort size (n = 11) indicates that validation in larger MRD-focused studies is required before clinical implementation for treatment monitoring. This dPCR-based platform provides accessible, quantitative detection without requiring knowledge of clonal shifts or specific genomic landscape, offering potential advantages for resource-limited settings such as those represented in our Mexican pediatric cohort.

Additionally, immune checkpoint gene analysis revealed significantly higher expression of CD276 and ICOSLG in the high-risk group compared to the low-risk group. Our findings suggest that serum exosomal circRNAs may be promising prognostic biomarkers in NPC, warranting further functional and clinical validation.

These findings suggest that CST7+ macrophages/monocytes are associated with immunotherapy response by correlating with cytotoxic T-cell activation through the ICOSL/ICOS pathway. The observed interaction highlights the potential for combining immune checkpoint inhibitors (ICIs) with ICOS/ICOSL agonistic antibodies to enhance and sustain long-term immunotherapy efficacy in patients with melanoma.

These findings were further corroborated by our single-cell RNA data and multiplex immunohistochemistry results, which provided additional substantiation for the observed interactions. These observations regarding the interaction between the tumor microenvironment and nasopharyngeal carcinoma have significant clinical implications for the future treatment of NPC.

In addition, KU decreased the proliferation marker, antigen Kiel 67 (Ki67⁺), and HSP90⁺ cell populations within tumors. Together, these findings demonstrate that UA/KU targets the HSP90-AhR axis, suppresses immune evasion pathways, and offers a novel immunomodulatory approach for lung cancer therapy.

Our study identified molecular biomarkers for pathological and survival outcomes, which may inform optimal treatment decision-making, guide postoperative therapy, and improve survival outcomes for stage II-III patients with resectable NSCLC.

Using peripheral blood biomarkers, we characterized immune subtypes of osteosarcoma, and developed a predictive model for metastasis. These biomarkers may serve as potential therapeutic targets for future immunotherapy.

Through single-cell analysis of published and in-house datasets, TRAF3IP3 exhibited selective enrichment in NPC-like and MES-like tumor cells, and showed a dual functionality in mediating T-Cell Exhaustion. Targeting TRAF3IP3 emerges as a promising avenue to combat immunotherapy resistance, particularly in glioma, thus paving the way for precision medicine.

This study focused on understanding the LAIP in AML before and after therapeutic intervention. The study highlights the potential of using single-cell LAIP profiling and immune mediator measurements to monitor therapy response and identify measurable residual disease and therapy resistant cell populations in AML.

Machine learning analysis demonstrated that random forest (RF) was the most effective model, achieving AUC values of 0.998, 0.968, and 0.998 in the training, CGGA-693 validation, and CGGA-325 validation cohorts, respectively, suggesting high predictive accuracy. This study identifies novel recurrence-associated molecular signatures and establishes a machine learning-based predictive model in IDH-wildtype histological GBM.